Expert Opinion on Investigational Drugs

Article	Citations
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	108
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	80
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	79
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	77
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	74
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	71
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	63
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	61
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	58
A randomized, phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	58
Theranostic strategies in sarcoma: preliminary clinical evidence	55
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	54
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	44
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	44
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	43
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	43
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials	37
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	37
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	34
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	31
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential	29
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	28
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	27
Emerging treatments for chronic urticaria	26
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials	26

Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	24
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	24
Endothelin receptor antagonists for diabetic kidney disease: back to the future?	24
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	23
Potassium channel modulators and schizophrenia: an overview of investigational drugs	22
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	22
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	21
Investigational drugs for the treatment of dysmenorrhea	21
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia	20
Ewing sarcoma: investigational mono- and combination therapies in clinical trials	20
Investigational drugs for immune thrombocytopenia	20
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development	19
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials	19
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer	17
IgA nephropathy: an overview of drug treatments in clinical trials	17
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics	17
Recent developments in adjunct therapies for type 1 diabetes	17
Current options and investigational drugs for the treatment of eosinophilic esophagitis	17
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer	16
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study	16
Duchenne muscular dystrophy: promising early-stage clinical trials to watch	16
Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1	16
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration	15
Current experimental and early investigational agents for cardiac fibrosis: where are we at?	15
What is the progress of experimental drug development for fibromyalgia?	15
Novel systemic treatment approaches for metastatic pancreatic cancer	15
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer	15
NF1 alterations in cancers: therapeutic implications in precision medicine	15
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal	15
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists	15
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options	15
Preclinical therapeutics for sickle cell disease: modern developments and future considerations	15
Frontotemporal dementia: from genetics to therapeutic approaches	14
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease	14
Investigational new drugs for the treatment of leishmaniasis	14
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021	14
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials	14
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations	13
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents	13
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)	13
Assessing the clinical progress of the bispecific nanobody sonelokimab	13
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	13
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects	13
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps	12
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	12
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)	11
Low-dose aspirin for early COVID-19: does the early bird catch the worm?	11
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	11
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	11
JAK inhibitors for rheumatoid arthritis	11

Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	11
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials	11
Clinical development of tri-specific antibodies for immune-oncology	11
Immunotherapeutic strategies for treating opioid use disorder and overdose	11
Navafenterol for chronic obstructive pulmonary disease therapy	11
Investigational drugs for the treatment of olfactory dysfunction	11
Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials	11
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	11
Camrelizumab: an investigational agent for hepatocellular carcinoma	10
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies	10
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis	10
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus	10
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers	10
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study	10
Pharmacological agents for bone fracture healing: talking points from recent clinical trials	10
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies	10
JAK inhibitors in crohn’s disease: ready to go?	10
Investigational new drugs for the treatment of Dravet syndrome: an update	10
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials	9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections	9
Investigational anti IL-13 asthma treatments: a 2023 update	9
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress	9
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer	9
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep	9
Inflammation and Huntington’s disease – a neglected therapeutic target?	9
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma	9
Assessing potential of psilocybin for depressive disorders	9
Emerging agents for the treatment and prevention of stroke: progress in clinical trials	9
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension	9
The impact of current investigational drugs for acne on future treatment strategies	9
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs	9
Mantle cell lymphoma: what clinical progress in the last 5 years?	8
Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials	8
Islatravir: evaluation of clinical development for HIV and HBV	8
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH	8
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets	8
Preclinical prospects of investigational agents for hearing loss treatment	8
Retinal stroke: research models, targets and experimental drugs	8
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?	8
Prospects of current AXL-targeting therapies in early phase cancer trials	8
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials	8
A VEGF gene therapy approach for the treatment of patients with coronary artery disease and refractory angina: assessment of clinical development	7
Investigational drugs in early clinical development for portal hypertension	7
Investigational drugs for the treatment of acromegaly: new agents to transform therapy	7
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate	7
Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?	7
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma	7
Novel investigational drugs for alopecia areata and future perspectives	7
What have we learned from past failures of investigational drugs for Alzheimer’s disease?	7
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs	7
Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto-β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis	7
Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies	7
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-c	7
Novel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials	7
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study	7
Psoriasis: talking points from recent clinical trials	7
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents	7
Retatrutide: a triple incretin receptor agonist for obesity management	6
Developments and challenges for new and emergent preparations for male hypogonadism treatment	6
Psoriasis: a focus on upcoming oral formulations	6
AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation	6
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	6
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease	6
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	6
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects	6
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	6
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study	6
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications	6
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	6
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer	6
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	6
Investigational drugs for ischemic stroke: what’s in the clinical development pipeline for acute phase and prevention?	6
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	6
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review	6
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	6
Correction	6
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study	6
Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects	6
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials	6
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	6

Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver	6
Fibroblast growth factor therapies in biliary tract cancers: current and future state	6
Experimental drugs for the prevention or treatment of sensorineural hearing loss	6
Investigational drugs in early phase trials for myelofibrosis	6
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects	6
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects	6
Fezolinetant in the treatment of vasomotor symptoms associated with menopause	6
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies	5
Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis	5
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development	5
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?	5
Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: res	5
Long COVID [post-acute sequelae of coronavirus disease 2019]: experimental drugs for cardiopulmonary complications	5
A focused report on IFN-1 targeted therapies for lupus erythematosus	5
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation	5
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome	5
Investigational drugs inhibiting complement for the treatment of geographic atrophy	5
Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics	5
Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials	5
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled do	5
Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition?	5
First-in-human phase I studies of YJ001 spray applied to local skin in healthy subjects and patients with diabetic neuropathic pain	5
Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor—comprehensive review of early safety & efficacy data	5
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation	5
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action	5
Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials	5
Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?	4
A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion prote	4
Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments	4
Avasopasem for the treatment of radiotherapy-induced severe oral mucositis	4
KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases	4
Bladder cancer: shedding light on the most promising investigational drugs in clinical trials	4
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases	4
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options	4
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline	4
Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer	4
Early stage clinical trials for the treatment of hemophilia A	4
Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection	4
Factor IX stimulants in preclinical and early phase trials for hemophilia B treatment	4
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease	4
Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis	4
Experimental and new investigational drugs for the treatment of uterine fibroids	4
Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation	4
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke	4
Insulin sensitizers in 2023: lessons learned and new avenues for investigation	4
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?	4
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	3
Prospects for multi-focal motor neuropathy treatment by complement inhibition	3
Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma	3
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer	3
Venetoclax in acute myeloid leukemia	3
Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit	3
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?	3
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what’s new?	3
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidat	3
Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?	3
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers	3
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	3
Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers	3
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	3
Atezolizumab: an investigational agent for the treatment of biliary tract cancer	3
Metabolic dysfunction and insulin sensitizers in acute and chronic disease	3
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease	3
Prospect of CAR T-cell therapy in acute myeloid leukemia	3
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	3
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature	3
Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects	3
Investigational drugs in clinical trials for macular degeneration	3
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential	3
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension	3
Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial	3
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review	3
Therapies in preclinical and clinical development for Angelman syndrome	3
Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer	3
Investigational drugs for HIV: trends, opportunities and key players	3
Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy	3
Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure	3
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	3
An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions	3
The role of phosphodiesterase 9A inhibitors in heart failure	3
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond	3
Investigational treatment strategies in glioblastoma: progress made and barriers to success	3
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	3
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?	3